The FDA has approved DECNUPAZ (pivekimab sunirine-pvzy), the first antibody-drug conjugate (ADC) for treating blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer. This approval is based on positive results from the Phase 1/2 CADENZA trial, showing significant response rates in both newly diagnosed and relapsed patients. DECNUPAZ can be administered in an outpatient setting, offering a new treatment option for patients with limited therapies. AbbVie, the developer, highlights this as a major advancement for difficult-to-treat blood cancers.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
